July 17, 2024 07:00 AM EDT
Financing

Three months af­ter delist­ing, NGM Bio is back with $122M for slimmed-down pipeline

Kyle LaHucik

Senior Reporter

NGM Bio­phar­ma­ceu­ti­cals is push­ing ahead with two of its 10 clin­i­cal-stage pro­grams af­ter the drug de­vel­op­er was tak­en off the Nas­daq by one of its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times